

**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of Rainbow Children's Medicare Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Rainbow Children's Medicare Limited (the "Company") for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

  
per Atin Bhargava  
Partner

Membership No.: 504777



UDIN: 24504777BKP86757

Place: Hyderabad

Date: August 13, 2024

Rainbow Children's Medicare Limited (formerly known as 'Rainbow Children's Medicare Private Limited')

CIN: L85110TG1998PLC029914

Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034  
Corporate Office : 8-2-19/1/a, Dault Arcade, Karvy lane, Road No.11, Banjara Hills, Hyderabad, Telangana-500034  
Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in

Statement of Unaudited Standalone Financial Results for the quarter ended 30 June 2024

(Rs. in Millions except per share data)

Particulars	Quarter ended			Year ended
	30 June 2024	31 March 2024	30 June 2023	31 March 2024
	Unaudited	Audited	Unaudited	Audited
<b>INCOME</b>				
1. Revenue from operations	3,150.23	3,257.57	2,703.50	12,365.62
2. Other income	114.82	122.35	75.93	369.48
<b>3. Total income [1+2]</b>	<b>3,265.05</b>	<b>3,379.92</b>	<b>2,779.43</b>	<b>12,735.10</b>
<b>4. EXPENSES</b>				
a. Cost of materials consumed	412.61	400.64	359.72	1,571.27
b. Employee benefits expense	470.55	473.77	415.67	1,687.09
c. Finance costs	174.39	161.13	138.49	560.66
d. Depreciation and amortisation expense	324.38	305.68	236.40	1,051.51
e. Professional fees to doctors	797.76	739.14	656.48	2,877.30
f. Other expenses	569.07	615.32	446.17	2,095.10
<b>Total expenses</b>	<b>2,748.76</b>	<b>2,695.68</b>	<b>2,252.93</b>	<b>9,842.93</b>
<b>5. Profit before tax [3-4]</b>	<b>516.29</b>	<b>684.24</b>	<b>526.50</b>	<b>2,892.17</b>
<b>6. Tax expenses:</b>				
a. Current tax	151.38	137.37	147.37	745.43
b. Deferred tax (credit)/expense	(22.36)	42.51	(14.16)	(2.17)
<b>Total tax expense</b>	<b>129.02</b>	<b>179.88</b>	<b>133.21</b>	<b>743.26</b>
<b>7. Profit after tax [5-6]</b>	<b>387.27</b>	<b>504.36</b>	<b>393.29</b>	<b>2,148.91</b>
<b>8. Other comprehensive income</b>				
<i>Items that will not be reclassified subsequently to the Statement of Profit or Loss</i>				
Re-measurement gain on defined benefit obligation	1.21	12.06	1.21	17.21
Income tax effect	(0.30)	(3.03)	(0.30)	(4.33)
<b>Other comprehensive income, net of tax</b>	<b>0.91</b>	<b>9.03</b>	<b>0.91</b>	<b>12.88</b>
<b>9. Total comprehensive income [7+8]</b>	<b>388.18</b>	<b>513.39</b>	<b>394.20</b>	<b>2,161.79</b>
<b>10. Paid-up equity share capital (Face value of Rs. 10 each)</b>	<b>1,015.02</b>	<b>1,015.02</b>	<b>1,015.02</b>	<b>1,015.02</b>
<b>11. Other equity</b>				<b>11,837.49</b>
<b>12. Earning per share (Face value of share Rs.10 each)</b>				
a. Basic (Rs)	3.82	4.97	3.87	21.17
b. Diluted (Rs)	3.82	4.97	3.87	21.17
	(Not annualised)	(Not annualised)	(Not annualised)	



**Notes :**

- The above statement of unaudited standalone financial results of Rainbow Children's Medicare Limited ("the Company"), which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and in terms of Regulation 33 of Securities and Exchange Board of India ("SEBI") (Listing Obligations and Disclosure Requirements) Regulations, 2015 were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 August 2024. The Statutory Auditors have carried out a limited review on the unaudited standalone financial results and issued an unmodified report thereon.
- The standalone figures for the fourth quarter ended 31 March 2024 are the balancing figures between published audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year.
- Final dividend for the financial year 2023-24 of Rs. 3 per Equity Share of Rs. 10 each aggregating to Rs. 304.64 million was approved by the shareholders at the 26th Annual General Meeting held on 30 July 2024 and the same was paid on 30 July 2024.
- During the financial year 2022-23, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each of the Company for at an issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share, eligible employees bidding in the employee's reservation portion were offered a discount of Rs. 20 per equity share) aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity shares aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 10 May 2022.  
The Company has received a net amount of Rs. 2,661.40 million (net of Company's share of IPO expenses Rs. 138.60 million which are proportionately allocated between Company and selling shareholders as per the respective offer size) from proceeds out of fresh issue of Equity Shares. The Company's share of IPO expenses Rs. 138.60 million has been adjusted with securities premium as per the Companies Act, 2013.

**Details of utilisation of IPO proceeds:**

Objects of the issue	Amount as proposed in offer document (A)	Amount to be spent as per offer document up to 31 March 2025* (B)	Amount to be spent as per offer document for the year 2024-25 (C)	(Rs. in Millions)	
				Utilisation up to 30 June 2024 (D)	Unspent balance as at 30 June 2024 (E) = (B) - (D)
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited, in full	400.00	400.00	-	400.00	-
Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1,700.00	1,700.00	200.00	1,499.08	200.92
General corporate purposes *	561.40	576.10	-	576.10	-
<b>Total</b>	<b>2,661.40</b>	<b>2,676.10</b>	<b>200.00</b>	<b>2,475.18</b>	<b>200.92</b>

\* During the financial year 2023-24, the Company has received an amount of Rs. 14.70 million towards the Company's share of unspent IPO expenses. The same has been adjusted with securities premium as per the Companies Act, 2013. The Board of Directors of the Company in their meeting held on 30 October 2023 has approved to spend the amount of Rs. 14.70 million towards the General corporate purposes, refer column (B) in the table above. After this change amount to be utilised for General corporate purposes is Rs. 576.10 million.

Net IPO proceeds which were unutilised as at 30 June 2024 amounting to Rs. 200.92 million (column E) were temporarily invested in fixed deposits and held in current account with banks.

- During the financial year 2022-23, the Company secured bids for two land parcels in Gurugram, Haryana, measuring 9,414.87 square meters (approximately 2.32 acres) and 4,987 square meters (approximately 1.23 acres), located in Sector 44 and Sector 56, respectively. These parcels were auctioned by Haryana Shehri Vikas Pradhikaran ("HSVP"). On 05 July 2023, the Company received the allotment letters from HSVP, confirming the allocation of these properties following the full payment of consideration amounts totaling Rs. 1,338.62 million for the Sector 44 parcel and Rs. 290.45 million for the Sector 56 parcel. Subsequently, on 04 July 2024 the Company completed the registration of these properties.
- Subsequent to the quarter ended 30 June 2024, the Company has allotted 44,000 equity shares Rs. 10 each, consequent to the exercise of the stock options by an employee of the Company under the Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023 ("Stock Unit Plan 2023"). The allotment has been approved by the Nomination and Remuneration committee on 17 July 2024.
- The Company is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the Company are concentrated in India, and hence, the Company is considered to operate only in one geographical segment.
- The standalone financial results for the quarter ended 30 June 2024, are available on the BSE Limited website (URL: [www.bseindia.com](http://www.bseindia.com)), the National Stock Exchange of India Limited website (URL: [www.nseindia.com](http://www.nseindia.com)) and on the Company's website (URL: [www.rainbowhospitals.in](http://www.rainbowhospitals.in)).

for and on behalf of the Board of Directors of  
Rainbow Children's Medicare Limited



**Dr. Ramesh Kancharla**  
Chairman and Managing Director  
DIN: 00212270

Place : Hyderabad  
Date : 13 August 2024

**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of Rainbow Children's Medicare Limited Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended****Review Report to  
The Board of Directors  
Rainbow Children's Medicare Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Rainbow Children's Medicare Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group"), for the quarter ended June 30, 2024 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:

**Holding company:**

Rainbow Children's Medicare Limited

**Subsidiaries:**

- a) Rainbow Speciality Hospitals Private Limited
- b) Rosewalk Healthcare Private Limited
- c) Rainbow C R O Private Limited
- d) Rainbow Fertility Private Limited
- e) Rainbow Children's Hospital Private Limited
- f) Rainbow Woman & Children's Hospital Private Limited



# **S.R. BATLIBOI & ASSOCIATES LLP**

Chartered Accountants

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. The accompanying Statement includes unaudited interim financial results in respect of 6 subsidiaries, whose interim financial results reflect total revenues of Rs 171.75 million, total net profit after tax of Rs 10.05 million, total comprehensive income of Rs 10.17 million, for the quarter ended June 30, 2024.

The unaudited interim financial results of these subsidiaries have not been reviewed by any auditor and have been approved and furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the affairs of these subsidiaries, is based solely on such unaudited interim financial results. According to the information and explanations given to us by the Management, these interim financial results are not material to the Group.

Our conclusion on the Statement in respect of matters stated in para 6 above is not modified with respect to our reliance on the work done and the reports of the other auditors and the financial results certified by the Management.

**For S.R. Batliboi & Associates LLP**

Chartered Accountants

**ICAI Firm registration number:** 101049W/E300004

  
per Atin Bhargava  
Partner

Membership No.: 504777

UDIN: 24504777BKDHNC2521



Place: Hyderabad

Date: August 13, 2024

**Rainbow Children's Medicare Limited (formerly known as 'Rainbow Children's Medicare Private Limited')**  
**CIN: L85110TG1998PLC029914**  
**Registered Office : 8-2-120/103/1, Survey No. 403, Road No.2, Banjara Hills, Hyderabad, Telangana-500034**  
**Corporate Office : 8-2-19/1/a, Daulet Arcade, Karvy lane, Road No.11, Banjara Hills, Hyderabad, Telangana-500034**  
**Tel: +91 40 4969 2244, e-mail : companysecretary@rainbowhospitals.in**

**Statement of Unaudited Consolidated Financial Results for the quarter ended 30 June 2024**

(Rs. in Millions except per share data)

Particulars	Quarter ended			Year ended
	30 June 2024	31 March 2024	30 June 2023	31 March 2024
	Unaudited	Audited	Unaudited	Audited
<b>INCOME</b>				
1. Revenue from operations	3,302.17	3,411.02	2,871.65	12,969.00
2. Other income	119.34	127.77	78.55	370.64
<b>3. Total income [1+2]</b>	<b>3,421.51</b>	<b>3,538.79</b>	<b>2,950.20</b>	<b>13,339.64</b>
<b>4. EXPENSES</b>				
a. Cost of materials consumed	424.79	419.39	383.99	1,652.80
b. Employee benefits expense	489.98	484.15	435.97	1,761.70
c. Finance costs	181.62	168.47	146.07	590.54
d. Depreciation and amortisation expense	341.43	322.98	253.28	1,120.82
e. Professional fees to doctors	849.64	788.31	698.39	3,053.66
f. Other expenses	600.52	663.75	476.26	2,211.99
<b>Total expenses</b>	<b>2,887.98</b>	<b>2,847.05</b>	<b>2,393.96</b>	<b>10,391.51</b>
<b>5. Profit before tax [3-4]</b>	<b>533.53</b>	<b>691.74</b>	<b>556.24</b>	<b>2,948.13</b>
<b>6. Tax expenses:</b>				
a. Current tax	156.53	140.43	156.80	770.39
b. Deferred tax (credit)/expense	(20.28)	40.66	(15.46)	(5.13)
<b>Total tax expense</b>	<b>136.25</b>	<b>181.09</b>	<b>141.34</b>	<b>765.26</b>
<b>7. Profit after tax [5-6]</b>	<b>397.28</b>	<b>510.65</b>	<b>414.90</b>	<b>2,182.87</b>
<b>8. Other comprehensive income</b>				
<i>Items that will not be reclassified subsequently to the Statement of Profit or Loss</i>				
Re-measurement gain on defined benefit obligation	1.34	11.99	1.23	17.70
Income tax effect	(0.31)	(3.04)	(0.31)	(4.36)
<b>Other comprehensive income, net of tax</b>	<b>1.03</b>	<b>8.95</b>	<b>0.92</b>	<b>13.34</b>
<b>9. Total comprehensive income [7+8]</b>	<b>398.31</b>	<b>519.60</b>	<b>415.82</b>	<b>2,196.21</b>
<b>Profit after tax attributable to:</b>				
Owners of the Company	395.33	509.73	409.95	2,170.01
Non-controlling interests	1.95	0.92	4.95	12.86
<b>Profit after tax</b>	<b>397.28</b>	<b>510.65</b>	<b>414.90</b>	<b>2,182.87</b>
<b>Other comprehensive income attributable to:</b>				
Owners of the Company	1.03	8.95	0.92	13.33
Non-controlling interests	0.00	-	0.00	0.01
<b>Other comprehensive income</b>	<b>1.03</b>	<b>8.95</b>	<b>0.92</b>	<b>13.34</b>
<b>Total comprehensive income attributable to:</b>				
Owners of the Company	396.36	518.68	410.87	2,183.34
Non-controlling interests	1.95	0.92	4.95	12.87
<b>Total comprehensive income</b>	<b>398.31</b>	<b>519.60</b>	<b>415.82</b>	<b>2,196.21</b>
<b>10. Paid-up equity share capital (Face value of Rs. 10 each)</b>	1,015.02	1,015.02	1,015.02	1,015.02
<b>11. Other equity</b>				11,574.25
<b>12. Earning per share (Face value of share Rs.10 each)</b>				
a. Basic (Rs)	3.89	5.02	4.04	21.38
b. Diluted (Rs)	3.89	5.02	4.04	21.38
	(Not annualised)	(Not annualised)	(Not annualised)	



**Notes :**

- The above statement of unaudited consolidated financial results of Rainbow Children's Medicare Limited ("the Company"), and its subsidiaries (the Company and its subsidiaries together referred to as "the Group") which have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under section 133 of Companies Act, 2013 ("the Act") read with relevant rules issued thereunder, other accounting principles generally accepted in India and guidelines issues by the Securities and Exchange Board of India ("SEBI") were reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective meetings held on 13 August 2024. The Statutory Auditors have carried out a limited review on the unaudited consolidated financial results and issued an unmodified report thereon.
- The consolidated figures for the fourth quarter ended 31 March 2024 are the balancing figures between published audited figures in respect of the full previous financial year and the published unaudited year to date figures up to the third quarter of the relevant financial year.
- Final dividend for the financial year 2023-24 of Rs. 3 per Equity Share of Rs. 10 each aggregating to Rs. 304.64 million was approved by the shareholders at the 26th Annual General Meeting held on 30 July 2024 and the same was paid on 30 July 2024.
- During the financial year 2022-23, the Company has completed Initial Public Offering of 29,168,579 Equity Shares of face value of Rs. 10 each of the Company for at an issue price of Rs. 542 per equity share (including a share premium of Rs. 532 per equity share, eligible employees bidding in the employee's reservation portion were offered a discount of Rs. 20 per equity share) aggregating to Rs. 15,808.49 million comprising a fresh issue of 5,167,679 Equity Shares aggregating to Rs. 2,800.00 million and an offer for sale of 24,000,900 Equity shares aggregating to Rs. 13,008.49 million. The equity shares of the Company were listed on National Stock Exchange of India Limited (NSE) and BSE Limited (BSE) w.e.f 10 May 2022.  
The Company has received a net amount of Rs. 2,661.40 million (net of Company's share of IPO expenses Rs. 138.60 million which are proportionately allocated between the Company and selling shareholders as per the respective offer size) from proceeds out of fresh issue of Equity Shares. The Company's share of IPO Expenses Rs. 138.60 million has been adjusted with securities premium as per Companies Act, 2013.

**Details of utilisation of IPO proceeds:**

(Rs. in Millions)

Objects of the issue	Amount as proposed in offer document (A)	Amount to be spent as per offer document up to 31 March 2025* (B)	Amount to be spent as per offer document for the year 2024-25 (C)	Status as at 30 June 2024	
				Utilisation up to 30 June 2024 (D)	Unspent balance as at 30 June 2024 (E) = (B) - (D)
Early redemption of NCDs issued by our Company to CDC Emerging Markets Limited, in full	400.00	400.00	-	400.00	-
Capital expenditure towards setting up of new hospitals and purchase of medical equipment for such new hospitals	1,700.00	1,700.00	200.00	1,499.08	200.92
General corporate purposes*	561.40	576.10	-	576.10	-
<b>Total</b>	<b>2,661.40</b>	<b>2,676.10</b>	<b>200.00</b>	<b>2,475.18</b>	<b>200.92</b>

\* During the financial year 2023-24, the Company has received an amount of Rs. 14.70 million towards the Company's share of unspent IPO expenses. The same has been adjusted with securities premium as per the Companies Act, 2013. The Board of Directors of the Company in their meeting held on 30 October 2023 has approved to spend the amount of Rs. 14.70 million towards the General corporate purposes, refer column (B) in the table above. After this change amount to be utilised for General corporate purposes is Rs. 576.10 million.

Net IPO proceeds which were unutilised as at 30 June 2024 amounting to Rs. 200.92 million (column E) were temporarily invested in fixed deposits and held in current account with banks.

- During the financial year 2022-23, the Company secured bids for two land parcels in Gurugram, Haryana, measuring 9,414.87 square meters (approximately 2.32 acres) and 4,978 square meters (approximately 1.23 acres), located in Sector 44 and Sector 56, respectively. These parcels were auctioned by Haryana Shehri Vikas Pradhikaran ("HSVP"). On 05 July 2023, the Company received the allotment letters from HSVP, confirming the allocation of these properties following the full payment of consideration amounts totaling Rs. 1,338.62 million for the Sector 44 parcel and Rs. 290.45 million for the Sector 56 parcel. Subsequently, on 04 July 2024 the Company completed the registration of these properties.
- Subsequent to the quarter ended 30 June 2024, the Company has allotted 44,000 equity shares of Rs 10 each, consequent to the exercise of the stock options by an employee of the Company under the Rainbow Children's Medicare Limited - Employee Stock Unit Plan 2023 ("Stock Unit Plan 2023"). The allotment has been approved by the Nomination and Remuneration committee on 17 July 2024.
- The Group is principally engaged in a single business segment viz., rendering medical and healthcare services. Further the business operation of the group are concentrated in India, and hence, the group is considered to operate only in one geographical segment.
- The consolidated financial results for the quarter ended 30 June 2024, are available on the BSE Limited website (URL: www.bseindia.com), the National Stock Exchange of India Limited website (URL: www.nseindia.com) and on the Company's website (URL: www.rainbowhospitals.in).
- The consolidated financial results include the financial results of Rainbow Children's Medicare Limited ('the Company') and the financial results of its subsidiaries, Rainbow C R O Private Limited, Rainbow Fertility Private Limited, Rainbow Women & Children's Hospital Private Limited, Rainbow Speciality Hospitals Private Limited, Rosewalk Healthcare Private Limited and Rainbow Children's Hospital Private Limited (together called as the "Group").

for and on behalf of the Board of Directors of  
Rainbow Children's Medicare Limited



**Dr. Ramesh Kancharla**  
Managing Director

Place : Hyderabad  
Date : 13 August 2024